It is known that the anti-PD-1 antibody nivolumab and the anti-CTLA-4 antibody ipilimumab can bring about hypopituitarism, thyroid disorder, adrenal cortex dysfunction, and type 1 diabetes mellitus. This evidence concerns the gene CTLA4 and diabetes mellitus.